Skip to main content

Rheumatoid Arthritis

      RT @DrMiniDey: Rheumatology Research Foundation Lecture: Learning lessons from @Google to harness #omics to better under

      Mrinalini Dey DrMiniDey

      3 years 11 months ago
      Rheumatology Research Foundation Lecture: Learning lessons from @Google to harness #omics to better understand #RA #ACR21 @RheumNow @RheumResearch https://t.co/NVAe2Rqo1O
      RT @RichardPAConway: @NamrataRheum on outcomes in RA patients on RTX who get COVID-19. ⬆️hospitalisation, ICU, mech

      Richard Conway RichardPAConway

      3 years 11 months ago
      @NamrataRheum on outcomes in RA patients on RTX who get COVID-19. ⬆️hospitalisation, ICU, mech ventilation, but not mortality (in this cohort) Abstr#1445 #ACR21 @RheumNow https://t.co/8RcrzTdEb0
      RT @Janetbirdope: Yup, another large database shows more #hospitalizations with #RheumatoidArthritis with #rituximab but

      Janet Pope Janetbirdope

      3 years 11 months ago
      Yup, another large database shows more #hospitalizations with #RheumatoidArthritis with #rituximab but NOT higher mortality in matched analysis. Abst#1445 #ACR21 @RheumNow https://t.co/9XV8iX10sA
      RT @Janetbirdope: You can <but not as frequently> treat to target in #RheumatoidArthritis with virtual v in person

      Janet Pope Janetbirdope

      3 years 11 months ago
      You can <but not as frequently> treat to target in #RheumatoidArthritis with virtual v in person visits. 45 docs in 18 practices comparing in person to virtual. In person wins but not by a large gap! Abst#1448 @dansolomon @RheumNow #ACR21 #ACRBest session today coming up https://t.co/8lcuMW0bwb
      RT @DrMiniDey: Does #baricitinib affect #fatigue in RA patients?

      👉🏼Results from RA-BEAM and RA-BEACON
      👉🏼4mg

      Mrinalini Dey DrMiniDey

      3 years 11 months ago
      Does #baricitinib affect #fatigue in RA patients? 👉🏼Results from RA-BEAM and RA-BEACON 👉🏼4mg baricitinib significantly reduced fatigue, starting week 16, compared to placebo 👉🏼Effect independent of disease activity in active RA Abs#1235 #ACR21 @RheumNow https://t.co/0SKhUKJHd7 https://t.co/R76wc56u6I
      RT @DrMiniDey: What predicts response to MTX in RA?
      👉🏼DAS28-ESR
      👉🏼RA duration
      👉🏼Pt global assessment
      ð

      Mrinalini Dey DrMiniDey

      3 years 11 months ago
      What predicts response to MTX in RA? 👉🏼DAS28-ESR 👉🏼RA duration 👉🏼Pt global assessment 👉🏼Swollen joint count Abs#1227 #ACR21 @RheumNow https://t.co/s942zvFiZ1
      RT @DrMiniDey: Plenary Abs#1428 #ACR21
      👉🏼Long-term #steroid use is common in RA incl in pts with high risk of #MAC

      Mrinalini Dey DrMiniDey

      3 years 11 months ago
      Plenary Abs#1428 #ACR21 👉🏼Long-term #steroid use is common in RA incl in pts with high risk of #MACE 👉🏼30days of steroids ➡️ 15% increased odds of MACE @RheumNow https://t.co/fCM3m04ruS https://t.co/FWGmAatYu5
      RT @bella_mehta: 26K Veterans data with RA #ACR21 plenary abst#1428
      30 days on glucocorticoids - ⬆️15% odds of Majo

      Bella Mehta bella_mehta

      3 years 11 months ago
      26K Veterans data with RA #ACR21 plenary abst#1428 30 days on glucocorticoids - ⬆️15% odds of Major Adverse Cardiovascular events @RheumNow @BethIWallace https://t.co/BOram4o2rp
      RT @AurelieRheumo: Role of GC on MACE in RA:
      US database analysis 26000+pts
      23% on GC &gt;90d/6mo
      Each 30days of GC dis

      Aurelie Najm AurelieRheumo

      3 years 11 months ago
      Role of GC on MACE in RA: US database analysis 26000+pts 23% on GC >90d/6mo Each 30days of GC dispensed ⏭15% increase in odds of MACE in the following 6month period! Adjustment on several confounders but not disease activity. #Abts1428 #ACR21 @RheumNow https://t.co/prdA7D5fLz https://t.co/F3wCcRAfuf
      ×